The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine

Objective: There is limited research on the impact of antidepressant treatment on family functioning. This study examines the impact of vortioxetine and agomelatine on family functioning using the Depression and Family Functioning Scale (DFFS). Methods: The DFFS was included in REVIVE, a randomized,...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2017-06, Vol.33 (6), p.1057-1066
Main Authors: François, Clément, Nielsen, Rebecca, Danchenko, Natalya, Williams, Valerie, Lançon, Christophe
Format: Article
Language:English
Subjects:
Acetamides - therapeutic use
Adolescent
Adult
Aged
Antidepressive Agents - therapeutic use
Depression
Depressive Disorder, Major - drug therapy
Double-Blind Method
Family functioning
Female
Health Status
Humans
Male
Middle Aged
Patient-reported outcomes
Piperazines - therapeutic use
Psychiatric Status Rating Scales
Quality of life
Sulfides - therapeutic use
Vortioxetine
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: There is limited research on the impact of antidepressant treatment on family functioning. This study examines the impact of vortioxetine and agomelatine on family functioning using the Depression and Family Functioning Scale (DFFS). Methods: The DFFS was included in REVIVE, a randomized, double-blind study of adults with major depressive disorder with inadequate response to antidepressant treatment who switched to vortioxetine or agomelatine. The prespecified DFFS analyses were performed using change from baseline to weeks 8 and 12, analyzed by mixed models for repeated measurements by treatment groups. Post hoc analyses compared DFFS scores for remitters and nonremitters. Patients were stratified into quartiles using DFFS scores, and scores on other clinical outcome assessments were compared. Results: Sizeable improvements in DFFS scores were observed from baseline to week 8 (−10.8, −7.9 for vortioxetine and agomelatine, respectively), with further improvements at week 12 (−13.5, −11.0). Vortioxetine (n = 189) was superior to agomelatine (n = 187) by 2.9 DFFS points at week 8 (p 
ISSN:0300-7995
1473-4877
DOI:10.1080/03007995.2017.1299701